论文部分内容阅读
目的:分析中晚期宫颈癌患者应用芪胶升白胶囊辅助顺铂同步治疗方案治疗的临床效果及对其生存质量的改善作用。方法:114例中晚期宫颈癌患者按随机数字表法分为对照组和治疗组,每组57例患者。对照组患者仅采用顺铂进行治疗,治疗组患者则采用芪胶升白胶囊辅助顺铂同步治疗。对比两组患者治疗后的临床效果、治疗前后生存质量及用药后不良反应发生情况。结果:治疗组患者治疗后临床总有效率(78.95%)和对照组的(54.39%)相比明显较高,具有统计学意义(P<0.05)。治疗组患者治疗后的生理、情感、功能、社会和家庭状态评分和对照组相比明显较高,具有统计学意义(P<0.05)。治疗组患者用药后的白细胞减少(5.26%)、血小板减少(5.26%)、恶心(5.26%)和对照组的白细胞减少(22.81%)、血小板减少(24.56%)、恶心(28.07%)相比明显较低,具有统计学意义(P<0.05);但两组的贫血、肝功能异常的发生率无明显差异,无统计学意义(P>0.05)。结论:中晚期宫颈癌患者应用芪胶升白胶囊辅助顺铂同步治疗方案治疗的效果明显,有效改善患者症状,改善机体的造血功能,患者生存质量得以改善,不良反应减少,安全可靠。
OBJECTIVE: To analyze the clinical effect and the improving effect on the quality of life of patients with advanced cervical cancer treated with the application of Qigelishen Capsule in combination with cisplatin. Methods: One hundred and seventy-four patients with advanced cervical cancer were divided into control group and treatment group by random number table. Each group included 57 patients. Patients in the control group were treated with cisplatin only, and patients in the treatment group were treated with cisplatin simultaneously. The clinical effects, the quality of life before and after treatment and the adverse reactions after treatment were compared between the two groups. Results: The total effective rate (78.95%) after treatment in the treatment group was significantly higher than that in the control group (54.39%), with statistical significance (P <0.05). The score of physical, emotional, functional, social and family status after treatment in the treatment group was significantly higher than that in the control group (P <0.05). After treatment, the number of leukopenia (5.26%), thrombocytopenia (5.26%), nausea (5.26%) and leukopenia (22.81%), thrombocytopenia (24.56%) and nausea (P <0.05). However, there was no significant difference between the two groups in the incidence of anemia and liver dysfunction (P> 0.05). Conclusion: The application of QGLB in synchronous treatment with cisplatin is effective in patients with advanced cervical cancer. It can effectively improve the symptoms and improve the hematopoietic function in patients with cervical cancer. The patients’ quality of life is improved, the adverse reactions are reduced, and the patients are safe and reliable.